Eli Lilly To Present Fresh Data On Foundayo, Retatrutide In Europe – Here’s Why Berenberg Sees A 21% Potential Upside In ...
Berenberg sees potential upside to Lilly’s full-year 2026 revenue forecast, which ranges from $85 billion to $87 billion. Lilly to present latest data from the Phase 3 Triumph-2 results for Retatrutide, its investigational obesity drug. Lilly will also …